Adverum Biotechnologies, Inc. ADVM Income Statement

Adverum biotechnologies, inc. (ADVM)

Income statement / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13	Jun'13
Collaboration and license revenue
-	0	-	-	1,612	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration and license revenue
-	-	-	-	-	-	-	-	-	-	-	1,652	1,455	1,927	2,485	2,381	2,319	1,562	813	745	572	0	0	0	-	-
Government grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Operating expenses:
Research and development
40,419	40,687	45,223	47,470	50,133	50,505	46,297	43,572	39,839	35,723	33,813	33,276	31,670	30,964	30,125	27,296	25,462	25,496	23,719	21,687	16,976	10,300	5,215	0	0	0
General and administrative
28,376	25,284	22,721	24,768	24,560	23,415	23,351	18,236	20,857	21,592	22,976	24,026	24,355	24,952	26,437	26,282	22,107	20,113	14,880	11,415	7,998	4,876	2,672	0	0	0
Impairment of intangible asset
-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill impairment charge
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
68,795	65,971	72,944	77,238	79,693	78,920	69,648	61,808	60,696	68,515	68,383	118,016	116,739	108,003	108,255	56,151	50,142	45,609	38,599	33,102	24,974	15,176	7,887	0	0	0
Operating loss
-68,545	-65,651	-72,041	-75,842	-78,081	-76,917	-68,015	-60,205	-58,847	-66,639	-66,575	-116,364	-115,284	-106,076	-105,770	-53,770	-47,823	-44,047	-37,786	-32,357	-24,402	-14,777	-7,542	0	0	0
Other income:
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18	46	66	0	0	0
Other income, net
-	-	4,731	4,676	-	-	3,387	2,957	2,700	2,112	1,576	1,135	762	629	540	434	370	296	153	37	-21	-36	-4	0	0	0
Change in fair value of embedded derivative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	759	772	490	0	0	0
Loss on extinguishment of related-party convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-
Other income, net
-	0	-	-	-	0	-	-	-	-	-	1,135	762	629	540	434	370	297	-136	-893	-1,002	-1,049	-749	0	0	0
Net loss before income taxes
-	0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax benefit
-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-64,486	-61,220	-66,060	-69,916	-72,627	-71,757	-64,628	-57,248	-56,147	0	0	0	-	-105,447	-105,230	-53,336	-	-43,750	-37,922	-33,250	-25,404	-15,826	-8,291	0	0	0
Deemed dividend
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-
Net loss attributable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0
Other comprehensive income:
Net unrealized gain on marketable securities
33	66	115	154	168	49	31	-77	-182	-96	-137	-88	6	-18	-10	35	-6	0	0	0	-	-	-	-	-	-
Foreign currency translation adjustment
41	44	55	113	-4	-353	-536	-731	-774	-431	-271	-134	-2	-3	3	7	-15	-40	-24	0	-	0	0	-	-	-
Foreign currency translation adjustment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Comprehensive loss
-64,412	-61,110	-65,890	-69,649	-72,463	-72,061	-65,133	-58,056	-57,103	-64,279	-64,632	-114,676	-113,743	-105,468	-105,237	-53,294	-47,474	-43,764	-37,936	-33,310	-25,421	-15,838	-8,303	0	0	0
Net loss per share - basic and diluted
-0.30	-0.25	-0.23	-0.23	-0.24	-0.34	-0.30	-0.30	-0.32	-0.32	-0.27	-0.38	-0.46	-0.35	-1.76	-0.57	-0.55	-0.55	-0.38	-0.38	0.76	-0.50	-2.27	-0.45	-0.22	-0.20
Weighted-average common shares outstanding-basic and diluted
65,059	64,484	63,740	63,125	63,260	62,454	62,366	57,420	46,110	43,381	43,009	42,144	41,429	41,416	35,044	27,095	25,789	25,685	25,555	24,887	22,864	16,394	3,673	3,673	3,673	3,672